Drug-drug interactions: where do we go from here?

Affiliations

Comment

David N Juurlink. J Am Pharm Assoc (2003). 2004 Mar-Apr.

. 2004 Mar-Apr;44(2):128, 131-2, 134.

doi: 10.1331/154434504773062573.

¹ Division of General Internal Medicine, Sunnybrook and Women's College Health Sciences Center, Toronto, Ontario, Canada. dnj@ices.on.ca

No abstract available

Comment in

Drug interaction screens are pharmacists' responsibility.
Alayeto ME. Alayeto ME. J Am Pharm Assoc (2003). 2005 Mar-Apr;45(2):116, 119. doi: 10.1016/s1544-3191(15)31717-9. J Am Pharm Assoc (2003). 2005. PMID: 15868748 No abstract available.

Concordance of severity ratings provided in four drug interaction compendia.
Abarca J, Malone DC, Armstrong EP, Grizzle AJ, Hansten PD, Van Bergen RC, Lipton RB. Abarca J, et al. J Am Pharm Assoc (2003). 2004 Mar-Apr;44(2):136-41. doi: 10.1331/154434504773062582. J Am Pharm Assoc (2003). 2004. PMID: 15098847
Identification of serious drug-drug interactions: results of the partnership to prevent drug-drug interactions.
Malone DC, Abarca J, Hansten PD, Grizzle AJ, Armstrong EP, Van Bergen RC, Duncan-Edgar BS, Solomon SL, Lipton RB. Malone DC, et al. J Am Pharm Assoc (2003). 2004 Mar-Apr;44(2):142-51. doi: 10.1331/154434504773062591. J Am Pharm Assoc (2003). 2004. PMID: 15098848